Vermillion said it has raised a net of just under $12 million through a previously announced private placement. The Texas-based molecular diagnostics company also issued warrants that could boost that number another $18.3 million if and when the warrants are exercised.
Edwards Lifesciences has watched its share price tank about 19% since late last month, and now the company is plotting a $750 million stock buyback to reaffirm investor confidence, with CEO Michael Mussallem pitching in $5 million of his own.
C.R. Bard will fork over $48.3 million to settle allegations that it resorted to kickbacks to boost the use of its radioactive brachytherapy seeds to treat prostate cancer.
The FDA has been inspecting more and more medical device manufacturers over the past 5 years, and that's resulted in an 8-year peak in warning letters issued, according to a study.
OrbusNeich Medical accuses Boston Scientific of using a U.K. subsidiary to circumvent a preliminary court injunction in Germany that prevented the sale of some of its stents at the center of a patent dispute between the two companies.
Invacare has been hamstrung by an FDA consent decree, halting production at an Ohio plant, but the company is moving back toward normalcy, completing the first of three audits.
A U.K. startup is partnering with a Japanese company in what has become an increasingly important focus for diagnostics developers: tests that can spot lung cancer in its earliest stages when there is a chance to beat it back.
A year after HemCon Medical Technologies filed for Chapter 11 reorganization following the loss of a patent fight, the Oregon maker of gels and dressings has been sold.
Goldman Sachs is the latest multinational to see promise in India's surging medical tech industry. The global investment bank invested about $20 million in BPL Medical Technologies to help the medical device and instrument company's expansion plans.
Colorado's Lanx has wrapped up a $15 million Series C, money the devicemaker will use to market its spinal fusion technologies around the globe.
As its net profits careen into the red, Theragenics is considering a buyout offer worth up to $71.4 million from private equity outfit Juniper.
Israel has a relatively small share of the global medical device industry now, but the country is poised for some real growth in the sector and can brag about a large number of patents in the space.
Swiss cardiac stent maker Biosensors International will pay at least $51 million for U.S.-based Spectrum Dynamics, a developer of high-definition medical imaging technology.
Sorin picked up the FDA's blessing to market its SmartView remote monitoring system, which allows physicians to keep tabs on patients with implanted cardiac devices while they're at home.
Boston Scientific CEO Michael Mahoney predicts a long-awaited return to growth for the company in the second half of 2013, driven largely by five new products acquired through acquisitions. And Watchmen may have the biggest expectations behind it of the bunch.
Michigan State University researchers, working with their counterparts at the University of Malawi, say they've come up with a blood test that can spot children more likely to develop an especially dangerous form of malaria. Details of the breakthrough are published in the Journal of Infectious Diseases.
CareFusion grossed about $901 million in sales last quarter, a 2% decline due largely to slumping demand for the company's dispensing technologies and respiratory devices.
St. Jude Medical's much-scrutinized defibrillator leads remained almost 100% safe from abrasion and mechanical failure after 5 years, according to an independent analysis, results the company hopes will quiet alarm from regulators and competitors.
Sequenom has blazed a quick trail to the top of the prenatal testing space, and the company's revenue soared 158% to $38.5 million in the first quarter thanks to its flagship MaterniT21 Plus test.
Boston Scientific's Watchman is more effective in preventing stroke than standard-of-care warfarin, according to a study, giving the company some renewed hope for the device's FDA approval and eventual large market leadership.